- Home
- VERO vs KZIA Comparison
VERO vs KZIA Comparison
Compare VERO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERO
- KZIA
- Stock Information
- Founded
- VERO N/A
- KZIA 1994
- Country
- VERO Canada
- KZIA Australia
- Employees
- VERO N/A
- KZIA N/A
- Industry
- VERO Medical/Dental Instruments
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- VERO Health Care
- KZIA Health Care
- Exchange
- VERO Nasdaq
- KZIA Nasdaq
- Market Cap
- VERO 4.9M
- KZIA 5.1M
- IPO Year
- VERO N/A
- KZIA 1999
- Fundamental
- Price
- VERO $2.58
- KZIA $9.82
- Analyst Decision
- VERO
- KZIA Strong Buy
- Analyst Count
- VERO 0
- KZIA 2
- Target Price
- VERO N/A
- KZIA $14.00
- AVG Volume (30 Days)
- VERO 1.1M
- KZIA 656.0K
- Earning Date
- VERO 08-14-2025
- KZIA 08-05-2025
- Dividend Yield
- VERO N/A
- KZIA N/A
- EPS Growth
- VERO N/A
- KZIA N/A
- EPS
- VERO N/A
- KZIA N/A
- Revenue
- VERO $60,997,000.00
- KZIA $1,549,158.00
- Revenue This Year
- VERO N/A
- KZIA N/A
- Revenue Next Year
- VERO $7.47
- KZIA N/A
- P/E Ratio
- VERO N/A
- KZIA N/A
- Revenue Growth
- VERO N/A
- KZIA 248983.08
- 52 Week Low
- VERO $2.10
- KZIA $2.86
- 52 Week High
- VERO $14.50
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- VERO 51.60
- KZIA 58.07
- Support Level
- VERO $2.42
- KZIA $8.66
- Resistance Level
- VERO $2.71
- KZIA $10.37
- Average True Range (ATR)
- VERO 0.17
- KZIA 1.26
- MACD
- VERO -0.00
- KZIA -0.08
- Stochastic Oscillator
- VERO 26.09
- KZIA 64.50
About VERO Venus Concept Inc.
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.